Attaining and Maintaining Wellness in OCD (#6628)

A research study offering treatment for people who have obsessive-compulsive disorder (OCD) and are currently taking one of the following medications and still have unwanted symptoms:

  • Clomipramine (Anafranil)
  • Fluoxetine (Prozac)
  • Fluvoxamine (Luvox)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil)
  • Citalopram (Celexa)
  • Escitalopram (Lexapro)

The goal of the study is to understand whether patients with OCD on serotonin reuptake inhibitors (SRIs) who achieve wellness from EX/RP can safely discontinue their medication.

Eligible participants initially remain on a stable dose of their OCD medication and will receive cognitive-behavioral therapy (CBT) consisting of exposure and ritual prevention (EX/RP) twice a week for up to 12 weeks as additional treatment. 

Participants who become well (minimal-to-mild OCD symptoms) after the EX/RP will be randomly assigned to either continue their medication or begin to taper off their medication and have it gradually replaced with a placebo. 

All patients will be carefully monitored throughout the study for 24 weeks. No one who has not become well after 12 weeks of EX/RP will discontinue their medication. Individuals who do not improve significantly will be referred elsewhere to receive appropriate clinical treatment.

Visit the website and the clinical study website.

Organization: 
Center for OCD and Related Disorders at the New York State Psychiatric Institute at Columbia University; http://columbia-ocd.org/
Principal Investigator: 
H. Blair Simpson, MD, PhD
Eligibility Criteria: 

You may be eligible if

  • You have OCD.
  • You are between the ages of 18 and 75.
  • You are still having bothersome symptoms while taking one of the medications listed below for OCD.
  • You are interested in receiving no-cost therapy treatment that may improve your symptoms so that you may be able to stop taking your medication.
  • Clomipramine (Anafranil)
  • Fluoxetine (Prozac)
  • Fluvoxamine (Luvox)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil)
  • Citalopram (Celexa)
  • Escitalopram (Lexapro)
Contact: 
Dr. Marcia Kimeldorf at 212-543-5462 or 212-543-5367
Location: 
1051 Riverside Drive, New York, NY 10032
State: 
New York

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Health Impact Award

Award for Excellence


Independent Charities of America